Coulter Center

The Wallace H. Coulter Center (WHCC) at the University of Miami is focused on turning translational research in biomedical science and engineering into products by commercializing research projects that address an unmet clinical need and have market potential.

We work with investigators as a team to help them carry the project from a translational stage to a tangible product that impacts public health. The success metrics for our center include either successful licensing to an established company or creation of new professionally managed and financed UM start-ups. Emphasis is placed on ability to secure follow-on funding and translate into a successful license or start-up in less than 3 years.

Learn more about funding opportunities here.

Oversight Committee

  •  John Bixby – Vice Provost for Research, University of Miami
  • Gerry Brunk – Managing Director, Lumira Capital
  • Jason Campagna – Senior Vice President, The Medicines Company
  • Norma Kenyon – Chief Innovation Officer, Leonard M. Miller School of Medicine & Vice Provost for Innovation, University of Miami
  • Evan Kharasch – The Russell D. and Mary B. Shelden Professor of Anesthesiology & Director, Division of Clinical and Translational Research (DoCTR), Washington University in St. Louis
  • Martin Lehr – President and Chief Business Officer, Context Therapeutics
  • Mara Neal – Director – Research Awards, Wallace H. Coulter Foundation
  • John Newcomer – Executive Vice Dean and Professor of Clinical Biomedical Science, FAU Charles E. Schmidt College of Medicine and Interim Vice President for Research, FAU Division of Research
  • James O'Connell – Director, Office of Technology Transfer, University of Miami
  • Julia Owens – President and CEO, Atterocor
  • Robert Raynor – Director, Corporate Business Development, Beckman Coulter
  • Doug Reed – General Partner, Hatteras Venture Partners
  • Alison Tanner – Entrepreneur in Residence, Florida Institute Commercialization of Public Research
  • Rhys Williams – President, New World Angels
  • Rob Williamson – CEO, PharmAkea Therapeutics
  • Peter Young – Executive in Residence, A.M. Pappas & Associates